protoporphyrin ix has been researched along with Skin Neoplasms in 103 studies
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)." | 7.75 | A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009) |
| " In this study, we used 5-aminolevulinic (ALA) acid and 3 water soluble photosensitizers-PP(Arg)(2), PP(Ser)(2)Arg(2), PP(Ala)(2)Arg(2), all diamino acid derivatives of protoporphyrin IX-to treat benign papillomas in FVB/N mice induced by 7,12-dimethylbenz(a)anthracene (DMBA)-12-O-tetradecanoyl-phorbol-13-acetate (TPA)." | 7.75 | Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin. ( Dziadziuszko, H; Glosnicka, R; Graczyk, A; Jankowski, D; Jaskiewicz, K; Juzeniene, A; Kaliszewski, M; Kunikowska, D; Kwasny, M; Kwitniewski, M; Ma, LW; Moan, J; Peksa, R, 2009) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 7.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "With the application of CAP posttreatment, melanoma cell viability significantly decreased (80% were killed) compared to not using a light source (45% were killed) or using a UV light source (65% were killed)." | 5.46 | Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma. ( Geilich, BM; Keidar, M; Wang, M; Webster, TJ, 2017) |
| "5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)." | 3.75 | A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009) |
| " In this study, we used 5-aminolevulinic (ALA) acid and 3 water soluble photosensitizers-PP(Arg)(2), PP(Ser)(2)Arg(2), PP(Ala)(2)Arg(2), all diamino acid derivatives of protoporphyrin IX-to treat benign papillomas in FVB/N mice induced by 7,12-dimethylbenz(a)anthracene (DMBA)-12-O-tetradecanoyl-phorbol-13-acetate (TPA)." | 3.75 | Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin. ( Dziadziuszko, H; Glosnicka, R; Graczyk, A; Jankowski, D; Jaskiewicz, K; Juzeniene, A; Kaliszewski, M; Kunikowska, D; Kwasny, M; Kwitniewski, M; Ma, LW; Moan, J; Peksa, R, 2009) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 3.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "We present the kinetics of ALA-induced protoporphyrin IX (PP) accumulation and the results of ALA PDT treatment on two patients with different stages (stage I and stage III) of mycosis fungoides (MF)-type cutaneous T-cell lymphoma (CTCL)." | 3.70 | Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. ( Haik, J; Kostenich, G; Malik, Z; Orenstein, A; Tamir, J; Trau, H; Winkler, E, 2000) |
| "Treatment of non-melanoma skin cancers (NMSC) with topical photodynamic therapy (PDT) is a treatment of choice for many clinicians." | 2.74 | A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin. ( Ferguson, J; Lesar, A; Moseley, H, 2009) |
| "Protoporphyrin IX (PpIX) is an endogenous photosensitizer commonly used in photodynamic therapy." | 2.73 | Randomized control trial of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies. ( Brandt, MG; Jordan, K; Moore, CC, 2007) |
| " This method of enhancement was safely applied to a clinical PDT protocol with no unexpected adverse effects reported." | 2.73 | Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. ( Campbell, S; Curnow, A; Pye, A, 2008) |
| "A better understanding of why cancer cells fluoresce with 5-ALA would improve its use in cancer diagnostics and therapies." | 2.61 | In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? ( Gleadle, JM; MacGregor, MN; McNicholas, K, 2019) |
| "Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25-years." | 2.40 | 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. ( Berg, K; Giercksky, KE; Kongshaug, M; Moan, J; Nesland, JM; Peng, Q; Warloe, T, 1997) |
| "Protoporphyrin IX (PpIX) is an endogenous photosensitizer (PS) widely used, obtained by the administration of precursors such as aminolevulinic acid and methyl aminolevulinate." | 1.56 | Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies. ( Bagnato, VS; Fortunato, TC; Pratavieira, S; Requena, MB; Russignoli, PE; Salvio, AG; Vollet-Filho, JD, 2020) |
| "Non-melanoma skin cancers are the most frequently occurring type of cancer worldwide." | 1.48 | An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy. ( Anayo, L; Curnow, A; Magnussen, A; Perry, A; Wood, M, 2018) |
| "Of the 60 patients (20 Bowen's disease, 20 SCC, and 20 BCC), malignant neoplasms could be clearly distinguished from adjacent healthy tissue under fluorescence illumination (P < 0." | 1.48 | Topical application of Photofrin ( Chang, CJ; Chiang, YF; Hsiao, YC; Lin, YT, 2018) |
| "With the application of CAP posttreatment, melanoma cell viability significantly decreased (80% were killed) compared to not using a light source (45% were killed) or using a UV light source (65% were killed)." | 1.46 | Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma. ( Geilich, BM; Keidar, M; Wang, M; Webster, TJ, 2017) |
| "Metastatic skin cancer cells SKMEL-30 were treated by 5-ALA in dark and then they were irradiated by 90-femtosecond (fs) laser with different pulse powers for different durations." | 1.40 | Femtosecond laser induced photodynamic therapy on 5-ALA treated SKMEL-30 cells: an efficient theranostic strategy to combat melanoma. ( Gündoğdu, Y; Kara, R; Kars, MD; Kepceoğlu, A; Kılıç, HŞ, 2014) |
| "(R)L-sulforaphane (SF) is a compound that protects against erythema, but it can also induce DNA fragmentation that leads to cell death by apoptosis." | 1.35 | Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy. ( Juzeniene, A; Mikolajewska, P; Moan, J, 2008) |
| " However, in the case of deep, nodular-ulcerative lesions, the complete response rates are lower, possibly related to a lower bioavailability of PpIX." | 1.35 | Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. ( Ballini, JP; Dögnitz, N; Gabrecht, T; Lange, N; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2008) |
| "Etretinate-pretreated cells underwent apoptosis in response to ALA-based PDT." | 1.35 | Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy. ( Akita, Y; Ishida, N; Kuhara, T; Matsumoto, Y; Nakano, A; Takeo, T; Tamada, Y; Watanabe, D; Yamashita, N; Yanagishita, T, 2009) |
| "Depth of treatment of skin cancers were increased in CaNa2 EDTA-treated group." | 1.32 | Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy. ( Liu, HF; Xu, SZ; Zhang, CR, 2004) |
| "Ten basal cell carcinomas were coated with an ointment containing 10% ALA prior to excision; five served as controls." | 1.29 | Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. ( Landthaler, M; Sassy, T; Szeimies, RM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.97) | 18.7374 |
| 1990's | 18 (17.48) | 18.2507 |
| 2000's | 38 (36.89) | 29.6817 |
| 2010's | 43 (41.75) | 24.3611 |
| 2020's | 3 (2.91) | 2.80 |
| Authors | Studies |
|---|---|
| McEwan, C | 1 |
| Nesbitt, H | 1 |
| Nicholas, D | 1 |
| Kavanagh, ON | 1 |
| McKenna, K | 1 |
| Loan, P | 1 |
| Jack, IG | 1 |
| McHale, AP | 1 |
| Callan, JF | 1 |
| Schary, N | 1 |
| Novak, B | 1 |
| Kämper, L | 1 |
| Yousf, A | 1 |
| Lübbert, H | 1 |
| McNicholas, K | 1 |
| MacGregor, MN | 1 |
| Gleadle, JM | 1 |
| Requena, MB | 1 |
| Russignoli, PE | 1 |
| Vollet-Filho, JD | 1 |
| Salvio, AG | 2 |
| Fortunato, TC | 1 |
| Pratavieira, S | 1 |
| Bagnato, VS | 2 |
| León, D | 1 |
| Buchegger, K | 1 |
| Silva, R | 1 |
| Riquelme, I | 1 |
| Viscarra, T | 1 |
| Mora-Lagos, B | 1 |
| Zanella, L | 1 |
| Schafer, F | 1 |
| Kurachi, C | 1 |
| Roa, JC | 1 |
| Ili, C | 1 |
| Brebi, P | 1 |
| Wang, M | 1 |
| Geilich, BM | 1 |
| Keidar, M | 1 |
| Webster, TJ | 1 |
| Holien, T | 1 |
| Gederaas, OA | 1 |
| Darvekar, SR | 1 |
| Christensen, E | 1 |
| Peng, Q | 3 |
| Anayo, L | 1 |
| Magnussen, A | 1 |
| Perry, A | 2 |
| Wood, M | 2 |
| Curnow, A | 9 |
| Wu, Y | 1 |
| Wang, P | 1 |
| Zhang, L | 1 |
| Wang, B | 1 |
| Wang, X | 1 |
| Lin, YT | 1 |
| Hsiao, YC | 1 |
| Chiang, YF | 1 |
| Chang, CJ | 1 |
| Champeau, M | 1 |
| Vignoud, S | 1 |
| Mortier, L | 1 |
| Mordon, S | 1 |
| Larisch, P | 1 |
| Verwanger, T | 1 |
| Onder, K | 1 |
| Krammer, B | 1 |
| Fakhar-e-Alam, M | 1 |
| Kishwar, S | 1 |
| Willander, M | 1 |
| Xie, H | 1 |
| Xie, Z | 1 |
| Mousavi, M | 1 |
| Bendsoe, N | 2 |
| Brydegaard, M | 1 |
| Axelsson, J | 1 |
| Andersson-Engels, S | 5 |
| Salas-García, I | 2 |
| Fanjul-Vélez, F | 2 |
| Arce-Diego, JL | 2 |
| Kars, MD | 1 |
| Kara, R | 1 |
| Gündoğdu, Y | 1 |
| Kepceoğlu, A | 1 |
| Kılıç, HŞ | 1 |
| Salas-García, T | 1 |
| López-Gómez, A | 1 |
| Dorado-Fernández, M | 1 |
| Ruiz-Martínez, J | 1 |
| Rollakanti, KR | 1 |
| Anand, S | 2 |
| Davis, SC | 2 |
| Pogue, BW | 2 |
| Maytin, EV | 3 |
| Kulyk, O | 1 |
| Ibbotson, SH | 2 |
| Moseley, H | 5 |
| Valentine, RM | 3 |
| Samuel, ID | 1 |
| Bay, C | 1 |
| Togsverd-Bo, K | 2 |
| Lerche, CM | 2 |
| Haedersdal, M | 2 |
| El Hoshy, K | 1 |
| Bosseila, M | 1 |
| El Sharkawy, D | 1 |
| Sobhi, R | 1 |
| de Souza, AL | 1 |
| Marra, K | 1 |
| Gunn, J | 1 |
| Samkoe, KS | 1 |
| Kanick, SC | 1 |
| Chapman, MS | 1 |
| Hasan, T | 3 |
| Lima, CA | 1 |
| Goulart, VP | 1 |
| Bechara, EJ | 1 |
| Correa, L | 1 |
| Zezell, DM | 1 |
| Campbell, CL | 1 |
| Brown, CTA | 1 |
| Wood, K | 3 |
| Inada, NM | 1 |
| Cottrell, WJ | 2 |
| Paquette, AD | 1 |
| Keymel, KR | 1 |
| Foster, TH | 2 |
| Oseroff, AR | 3 |
| Mikolajewska, P | 1 |
| Juzeniene, A | 5 |
| Moan, J | 10 |
| Dögnitz, N | 1 |
| Salomon, D | 1 |
| Zellweger, M | 1 |
| Ballini, JP | 1 |
| Gabrecht, T | 1 |
| Lange, N | 1 |
| van den Bergh, H | 1 |
| Wagnières, G | 1 |
| de Haas, ER | 2 |
| de Bruijn, HS | 4 |
| Sterenborg, HJ | 3 |
| Neumann, HA | 2 |
| Robinson, DJ | 3 |
| Ishida, N | 2 |
| Watanabe, D | 2 |
| Akita, Y | 2 |
| Nakano, A | 2 |
| Yamashita, N | 1 |
| Kuhara, T | 1 |
| Yanagishita, T | 1 |
| Takeo, T | 1 |
| Tamada, Y | 2 |
| Matsumoto, Y | 2 |
| Donnelly, RF | 2 |
| McCarron, PA | 2 |
| Al-Kassas, R | 1 |
| Juzenas, P | 5 |
| Iani, V | 4 |
| Woolfson, AD | 2 |
| Honari, G | 1 |
| Elson, P | 1 |
| Pudroma, X | 1 |
| Ma, LW | 2 |
| Kwitniewski, M | 1 |
| Jankowski, D | 1 |
| Jaskiewicz, K | 1 |
| Dziadziuszko, H | 1 |
| Peksa, R | 1 |
| Kunikowska, D | 1 |
| Graczyk, A | 1 |
| Kwasny, M | 1 |
| Kaliszewski, M | 1 |
| Glosnicka, R | 1 |
| Lesar, A | 1 |
| Ferguson, J | 1 |
| Wang, KK | 1 |
| Mitra, S | 1 |
| Mizutani, K | 1 |
| Akimoto, M | 1 |
| Torchia, D | 1 |
| Cappugi, P | 1 |
| Liutkeviciūte-Navickiene, J | 1 |
| Mordas, A | 1 |
| Simkute, S | 1 |
| Bloznelyte-Plesniene, L | 1 |
| Tyrrell, J | 3 |
| Campbell, S | 4 |
| Kosaka, S | 1 |
| Kawana, S | 1 |
| Lee, CY | 1 |
| Kim, KH | 1 |
| Kim, YH | 1 |
| Ohgari, Y | 1 |
| Miyata, Y | 1 |
| Chau, TT | 1 |
| Kitajima, S | 1 |
| Adachi, Y | 1 |
| Taketani, S | 1 |
| Ortega-Quijano, N | 1 |
| Campbell, SM | 2 |
| Milla, LN | 1 |
| Cogno, IS | 1 |
| Rodríguez, ME | 1 |
| Sanz-Rodríguez, F | 1 |
| Zamarrón, A | 1 |
| Gilaberte, Y | 1 |
| Carrasco, E | 1 |
| Rivarola, VA | 1 |
| Juarranz, A | 1 |
| Brown, CT | 2 |
| Ibbotson, S | 1 |
| Tyrrell, JS | 1 |
| Morton, C | 1 |
| Harms, FA | 1 |
| de Boon, WM | 1 |
| Balestra, GM | 1 |
| Bodmer, SI | 1 |
| Johannes, T | 1 |
| Stolker, RJ | 1 |
| Mik, EG | 1 |
| van der Beek, N | 1 |
| de Leeuw, J | 1 |
| Demmendal, C | 1 |
| Bjerring, P | 1 |
| Liu, B | 1 |
| Farrell, TJ | 1 |
| Patterson, MS | 1 |
| Philipsen, PA | 1 |
| Poulsen, T | 1 |
| Wulf, HC | 2 |
| Wiegell, SR | 1 |
| Fabricius, S | 1 |
| Heydenreich, J | 1 |
| Enk, CD | 1 |
| Rosso, S | 1 |
| Bäumler, W | 2 |
| Baldursson, BT | 1 |
| Gaál, M | 1 |
| Kui, R | 1 |
| Hunyadi, Z | 1 |
| Kemény, L | 1 |
| Gyulai, R | 1 |
| Blake, E | 2 |
| Allen, J | 2 |
| Thorn, C | 1 |
| Shore, A | 1 |
| Kantere, D | 1 |
| Guldbrand, S | 1 |
| Paoli, J | 1 |
| Goksör, M | 1 |
| Hanstorp, D | 1 |
| Wennberg, AM | 2 |
| Smedh, M | 1 |
| Ericson, MB | 1 |
| Mathew, J | 1 |
| Helliwell, P | 1 |
| Sharfaei, S | 2 |
| Bissonnette, R | 2 |
| Diagaradjane, P | 1 |
| Madhuri, S | 1 |
| Aruna, P | 1 |
| Gupta, PK | 1 |
| Ganesan, S | 1 |
| Stakland, S | 1 |
| Bhasin, G | 1 |
| Kausar, H | 1 |
| Athar, M | 1 |
| Choudry, K | 1 |
| Brooke, RC | 1 |
| Farrar, W | 1 |
| Rhodes, LE | 1 |
| Liu, HF | 1 |
| Xu, SZ | 1 |
| Zhang, CR | 1 |
| Calin, MA | 1 |
| Gruia, Ml | 1 |
| Herascu, N | 1 |
| Coman, T | 1 |
| Ackermann, G | 1 |
| Abels, C | 2 |
| Szeimies, RM | 3 |
| Shen, SC | 1 |
| Lee, WR | 1 |
| Fang, YP | 2 |
| Hu, CH | 1 |
| Fang, JY | 1 |
| Thompson, MS | 1 |
| Svanberg, S | 4 |
| Johansson, T | 1 |
| Palsson, S | 1 |
| Derjabo, A | 1 |
| Kapostins, J | 1 |
| Stenram, U | 1 |
| Spigulis, J | 1 |
| Svanberg, K | 4 |
| Gilmore, BF | 1 |
| Morrow, DI | 1 |
| Murphy, DJ | 1 |
| Silva, JN | 1 |
| Filipe, P | 1 |
| Morlière, P | 1 |
| Mazière, JC | 1 |
| Freitas, JP | 1 |
| Cirne de Castro, JL | 1 |
| Santus, R | 1 |
| Star, WM | 4 |
| van't Veen, AJ | 1 |
| Munte, K | 1 |
| Smits, T | 1 |
| Kleinpenning, MM | 1 |
| Blokx, WA | 1 |
| van de Kerkhof, PC | 1 |
| van Erp, PE | 1 |
| Gerritsen, MJ | 1 |
| Brandt, MG | 1 |
| Moore, CC | 1 |
| Jordan, K | 1 |
| Pye, A | 1 |
| Tsai, YH | 1 |
| Wu, PC | 1 |
| Huang, YB | 1 |
| Lee, JB | 1 |
| Choi, JY | 1 |
| Chun, JS | 1 |
| Yun, SJ | 1 |
| Lee, SC | 1 |
| Oh, J | 1 |
| Park, HR | 1 |
| Roberts, DJ | 1 |
| Cairnduff, F | 1 |
| Rittenhouse-Diakun, K | 1 |
| Van Leengoed, H | 1 |
| Morgan, J | 1 |
| Hryhorenko, E | 1 |
| Paszkiewicz, G | 1 |
| Whitaker, JE | 1 |
| Iinuma, S | 1 |
| Farshi, SS | 1 |
| Ortel, B | 1 |
| Sassy, T | 1 |
| Landthaler, M | 1 |
| Martin, A | 2 |
| Tope, WD | 2 |
| Grevelink, JM | 1 |
| Starr, JC | 1 |
| Fewkes, JL | 1 |
| Flotte, TJ | 1 |
| Deutsch, TF | 1 |
| Anderson, RR | 2 |
| van der Veen, N | 2 |
| Berg, RJ | 1 |
| Svaasand, LO | 1 |
| Wyss, P | 1 |
| Wyss, MT | 1 |
| Tadir, Y | 1 |
| Tromberg, BJ | 1 |
| Berns, MW | 1 |
| Heyerdahl, H | 1 |
| Wang, I | 3 |
| Liu, DL | 1 |
| Berg, R | 1 |
| Warloe, T | 1 |
| Berg, K | 2 |
| Kongshaug, M | 1 |
| Giercksky, KE | 1 |
| Nesland, JM | 1 |
| Marcus, SL | 1 |
| Sobel, RS | 1 |
| Golub, AL | 1 |
| Carroll, RL | 1 |
| Lundahl, S | 1 |
| Shulman, DG | 1 |
| Ross, EV | 1 |
| Kollias, N | 1 |
| Gillies, R | 1 |
| Stringer, MR | 1 |
| Brown, SB | 1 |
| Gudmundson, F | 1 |
| Stenquist, B | 1 |
| Ternesten, A | 1 |
| Mölne, L | 1 |
| Rosén, A | 1 |
| Larko, O | 1 |
| Langer, S | 1 |
| Botzlar, A | 1 |
| Pahernik, S | 1 |
| Rick, K | 1 |
| Goetz, AE | 1 |
| af Klinteberg, C | 2 |
| Enejder, AM | 1 |
| Gadmar, OB | 1 |
| Ma, L | 1 |
| Lucroy, MD | 1 |
| Edwards, BF | 1 |
| Peavy, GM | 1 |
| Krasieva, TB | 1 |
| Griffey, SM | 1 |
| Stiles, JB | 1 |
| Madewell, BR | 1 |
| Canti, G | 1 |
| Cubeddu, R | 1 |
| Eker, C | 1 |
| Pifferi, A | 1 |
| Taroni, P | 1 |
| Valentini, G | 1 |
| De Rosa, FS | 1 |
| Marchetti, JM | 1 |
| Thomazini, JA | 1 |
| Tedesco, AC | 1 |
| Bentley, MV | 1 |
| Orenstein, A | 1 |
| Haik, J | 1 |
| Tamir, J | 1 |
| Winkler, E | 1 |
| Trau, H | 1 |
| Malik, Z | 1 |
| Kostenich, G | 1 |
| van den Akker, JT | 1 |
| Beijersbergen van Henegouwen, GM | 1 |
| Fischer, F | 1 |
| Dickson, EF | 1 |
| Kennedy, JC | 2 |
| Pottier, RH | 2 |
| Casas, A | 1 |
| Perotti, C | 1 |
| Fukuda, H | 1 |
| Rogers, L | 1 |
| Butler, AR | 1 |
| Batlle, A | 1 |
| Pross, DC | 1 |
| Mathews-Roth, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluorescence and Thermal Imaging of the Skin Before and During Photodynamic Therapy[NCT03167762] | 18 participants (Actual) | Interventional | 2017-06-22 | Completed | |||
| Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737] | 43 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ[NCT03025724] | 40 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for protoporphyrin ix and Skin Neoplasms
| Article | Year |
|---|---|
In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid?
Topics: Amino Acid Transport Systems; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogens; Ferrochelat | 2019 |
Photodynamic therapy for skin cancer: How to enhance drug penetration?
Topics: Aminolevulinic Acid; Drug Compounding; Humans; Liposomes; Micelles; Nanoparticles; Photochemotherapy | 2019 |
Daylight photodynamic therapy.
Topics: Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Meteorological Concepts; Photochemotherapy; Photo | 2015 |
[Fluorescence diagnosis of non-melanoma skin cancer].
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous | 2012 |
[Fluorescence diagnosis in dermatology].
Topics: Aminolevulinic Acid; Image Processing, Computer-Assisted; Optical Imaging; Protoporphyrins; Skin Dis | 2003 |
Photodynamic therapies: principles and present medical applications.
Topics: Aminolevulinic Acid; Bowen's Disease; Clinical Trials as Topic; Humans; Light; Lipoproteins, LDL; Ma | 2006 |
Photodynamic therapy of primary skin cancer: a review.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Female; Fo | 1995 |
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.
Topics: Aminolevulinic Acid; Forecasting; Heme; Humans; Neoplasms; Photochemotherapy; Protoporphyrins; Resea | 1997 |
Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status.
Topics: Aminolevulinic Acid; Animals; Endometrium; Female; Gastrointestinal Neoplasms; Humans; Laser Therapy | 1996 |
Beta-carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adolescent; Adult; Animals; Bacteria; Bacterial Physiological Phen | 1986 |
21 trials available for protoporphyrin ix and Skin Neoplasms
| Article | Year |
|---|---|
Enhancement of Photodynamic Therapy for Bowen's Disease Using Plum-Blossom Needling to Augment Drug Delivery.
Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Drug Delivery Systems; Female; Fluorescence; Humans; Mal | 2018 |
Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Optical Imaging; Photosensit | 2015 |
A quantitative study of in vivo protoporphyrin IX fluorescence build up during occlusive treatment phases.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Bandages; Female; Humans; Male; Metabolic C | 2017 |
A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin.
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Middl | 2009 |
Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Male; Photobleaching; Photochemotherap | 2010 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
PpIX fluorescence combined with auto-fluorescence is more accurate than PpIX fluorescence alone in fluorescence detection of non-melanoma skin cancer: an intra-patient direct comparison study.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Bowen's Disease; Carcinoma; Carcinoma, Basal Cell; False Neg | 2012 |
Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Oxygen; Pho | 2013 |
The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device.
Topics: Aminolevulinic Acid; Biological Transport; Carcinoma, Basal Cell; Injections; Oxygen; Photosensitizi | 2012 |
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car | 2003 |
Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; Lasers; Male; | 2006 |
Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; M | 2006 |
Randomized control trial of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies.
Topics: Aged; Female; Fluorescence; Humans; Male; Photosensitizing Agents; Prospective Studies; Protoporphyr | 2007 |
Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Humans; In Vi | 2008 |
Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; | 1995 |
Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid.
Topics: Administration, Oral; Aminolevulinic Acid; Carcinoma, Basal Cell; Drug Interactions; Fluorescence; H | 1998 |
In vivo detection of basal cell carcinoma using imaging spectroscopy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma, Basal Ce | 1999 |
Kinetic fluorescence studies of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation in basal cell carcinomas.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 1999 |
Preliminary evaluation of two fluorescence imaging methods for the detection and the delineation of basal cell carcinomas of the skin.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photosensi | 2000 |
A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy.
Topics: Aminolevulinic Acid; Animals; Dimethyl Sulfoxide; Humans; Mice; Mice, Hairless; Microscopy, Confocal | 2000 |
Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis; Ph | 1990 |
72 other studies available for protoporphyrin ix and Skin Neoplasms
| Article | Year |
|---|---|
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
Topics: Aminolevulinic Acid; Animals; Heterografts; Humans; Melanoma; Mice, SCID; Photochemotherapy; Skin Ne | 2016 |
Identification and pharmacological modification of resistance mechanisms to protoporphyrin-mediated photodynamic therapy in human cutaneous squamous cell carcinoma cell lines.
Topics: Aminolevulinic Acid; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2022 |
Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies.
Topics: Aminolevulinic Acid; Animals; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing Agents | 2020 |
Epigallocatechin Gallate Enhances MAL-PDT Cytotoxic Effect on PDT-Resistant Skin Cancer Squamous Cells.
Topics: Aminolevulinic Acid; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Catechin; Cell Death; Cell H | 2020 |
Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma.
Topics: Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Melanoma; Nanoparticles; Photochemotherapy; | 2017 |
Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.
Topics: Aminolevulinic Acid; Cell Culture Techniques; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutan | 2018 |
An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Epithelial Cells; Fibroblasts; Humans; Iron Chela | 2018 |
Topical application of Photofrin
Topics: Adult; Aged; Aged, 80 and over; Bowen's Disease; Carcinoma, Basal Cell; Dihematoporphyrin Ether; Fem | 2018 |
Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Humans; Iron Chelating Agents; Photochemothera | 2019 |
In vitro analysis of photosensitizer accumulation for assessment of applicability of fluorescence diagnosis of squamous cell carcinoma of epidermolysis bullosa patients.
Topics: Anthracenes; Carcinoma, Squamous Cell; Cell Line, Tumor; Epidermolysis Bullosa; False Positive React | 2013 |
Photodynamic effects of zinc oxide nanowires in skin cancer and fibroblast.
Topics: Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Fibroblasts; Humans; Male; Melanoma; Nanowir | 2014 |
Design and validation of a fiber optic point probe instrument for therapy guidance and monitoring.
Topics: Aminolevulinic Acid; Animals; Calibration; Carcinoma, Squamous Cell; Equipment Design; Fiber Optic T | 2014 |
Superficial radially resolved fluorescence and 3D photochemical time-dependent model for photodynamic therapy.
Topics: Carcinoma, Basal Cell; Humans; Models, Biological; Photochemical Processes; Photochemotherapy; Photo | 2014 |
Femtosecond laser induced photodynamic therapy on 5-ALA treated SKMEL-30 cells: an efficient theranostic strategy to combat melanoma.
Topics: Aged; Aminolevulinic Acid; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescence; Human | 2014 |
Noninvasive Optical Imaging of UV-Induced Squamous Cell Carcinoma in Murine Skin: Studies of Early Tumor Development and Vitamin D Enhancement of Protoporphyrin IX Production.
Topics: Animals; Carcinoma, Squamous Cell; Fluorescence; Gene Expression Regulation, Neoplastic; Mice; Optic | 2015 |
Skin tumor development after UV irradiation and photodynamic therapy is unaffected by short-term pretreatment with 5-fluorouracil, imiquimod and calcipotriol. An experimental hairless mouse study.
Topics: Aminolevulinic Acid; Aminoquinolines; Animals; Calcitriol; Carcinoma, Squamous Cell; Female; Fluorou | 2016 |
Can basal cell carcinoma lateral border be determined by fluorescence diagnosis?: Verification by Mohs micrographic surgery.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Diagnostic Techniques, Surgical; Female; Fl | 2016 |
Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Deferoxamine; Dose Fractio | 2016 |
Optimization and therapeutic effects of PDT mediated by ALA and MAL in the treatment of cutaneous malignant lesions: A comparative study.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Female; Mice; Photochemotherapy; Photosensit | 2016 |
Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Huma | 2008 |
Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy.
Topics: Aminolevulinic Acid; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Scree | 2008 |
Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relationship, Dru | 2008 |
Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Humans; Immunohistochemistry; Ki-67 Antigen; Mic | 2008 |
Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy.
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Squamous Cell; Cell Death; Dose-Response Relationship, Dr | 2009 |
Influence of formulation factors on PpIX production and photodynamic action of novel ALA-loaded microparticles.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Female; Gels; Mice; Mice, Inbred BALB C; Mi | 2009 |
Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Antimetabolites, Antineoplastic; Blo | 2009 |
A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin.
Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Hu | 2009 |
Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Carcinogens; Carcinoma, Squamous Cel | 2009 |
Simulations of measured photobleaching kinetics in human basal cell carcinomas suggest blood flow reductions during ALA-PDT.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Models, Cardiovascular; Photobleaching; Photoche | 2009 |
Heating increases protoporphyrin IX production in normal skin after delivery of 5-aminolevulinic acid by iontophoresis.
Topics: Adult; Aminolevulinic Acid; Hot Temperature; Humans; Iontophoresis; Male; Middle Aged; Photosensitiz | 2009 |
Intralesional photodynamic therapy: a comment on 'Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy' by Gerritsen et al.
Topics: Aminolevulinic Acid; Humans; Injections, Intralesional; Photochemotherapy; Protoporphyrins; Skin Neo | 2010 |
[Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 2009 |
Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT.
Topics: Aged; Aminolevulinic Acid; Dose-Response Relationship, Drug; Fluorescence; Humans; Keratosis, Actini | 2010 |
A case of Bowen's disease successfully treated by photodynamic therapy.
Topics: Aminolevulinic Acid; Bowen's Disease; Female; Humans; Middle Aged; Photochemotherapy; Photosensitizi | 2010 |
The efficacy of photodynamic diagnosis in defining the lateral border between a tumor and a tumor-free area during Mohs micrographic surgery.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carci | 2010 |
Quinolone compounds enhance delta-aminolevulinic acid-induced accumulation of protoporphyrin IX and photosensitivity of tumour cells.
Topics: Aminolevulinic Acid; Drug Synergism; Female; Ferric Compounds; Fluoroquinolones; HeLa Cells; Heme Ox | 2011 |
Photodynamic effects on basal cell carcinoma with topical Photosensitizer.
Topics: Administration, Topical; Carcinoma, Basal Cell; Dermatology; Humans; Monte Carlo Method; Necrosis; O | 2010 |
Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Drug Combinations; Female; Humans; Male; Metabolic Cle | 2011 |
Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy.
Topics: Aminolevulinic Acid; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion Molecules; Cel | 2011 |
Monte Carlo modeling of in vivo protoporphyrin IX fluorescence and singlet oxygen production during photodynamic therapy for patients presenting with superficial basal cell carcinomas.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Models, Biological; Monte Carlo Method; Phantoms | 2011 |
Oxygen-dependent delayed fluorescence measured in skin after topical application of 5-aminolevulinic acid.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Fluorescence; Male; Oxygen; Photosensitizing | 2011 |
Comparison of noninvasive photodynamic therapy dosimetry methods using a dynamic model of ALA-PDT of human skin.
Topics: Aminolevulinic Acid; Computer Simulation; Humans; Models, Statistical; Optics and Photonics; Oxygen | 2012 |
Porphyrin biodistribution in UV-exposed murine skin after methyl- and hexyl-aminolevulinate incubation.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Biological Availability; Female; Humans; Mice | 2012 |
Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations.
Topics: Aminolevulinic Acid; Dose-Response Relationship, Radiation; Europe; Geography, Medical; Humans; Isra | 2013 |
Anti-Stokes fluorescence from endogenously formed protoporphyrin IX--implications for clinical multiphoton diagnostics.
Topics: Humans; Infrared Rays; Lasers; Microscopy, Fluorescence, Multiphoton; Molecular Imaging; Protoporphy | 2013 |
Modelling fluorescence in clinical photodynamic therapy.
Topics: Aminolevulinic Acid; Humans; Models, Theoretical; Monte Carlo Method; Photobleaching; Photochemother | 2013 |
Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Drug Administration Schedule; Mice; Mice, H | 2002 |
In vivo pharmacokinetics of 8-aminolevulinic acid-induced protoporphyrin IX during pre- and post-photodynamic therapy in 7,12-dimethylbenz(a)nthracene-treated skin carcinogenesis in Swiss mice: a comparison by three-compartment model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Carcinogens; Female; Mice; Models, B | 2002 |
Photosensitizing effect of protoporphyrin IX in pigmented melanoma of mice.
Topics: Administration, Topical; Alamethicin; Aminolevulinic Acid; Animals; Cell Division; Hutchinson's Mela | 2002 |
Protoporphyrin-IX accumulation and cutaneous tumor regression in mice using a ferrochelatase inhibitor.
Topics: Animals; Enzyme Inhibitors; Female; Ferrochelatase; Light; Mice; Organometallic Compounds; Photochem | 2002 |
Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Edetic Acid; Female; Humans; Male; Middle Aged | 2004 |
The monitoring of the accumulation of protoporphyrin IX in Walker tumours by subcutaneous administration of delta-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Carcinoma 256, Walker; Injections, Subcutaneous; Photochemotherapy; Ph | 2004 |
In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium:YAG laser.
Topics: Administration, Cutaneous; Aluminum; Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Cell Line, | 2006 |
In vitro phototoxicity of 5-aminolevulinic acid and its methyl ester and the influence of barrier properties on their release from a bioadhesive patch.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, High Pressure Liqu | 2006 |
Fluorescence diagnosis in keratinocytic intraepidermal neoplasias.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Squamous Cell; Cell Proliferation; D | 2007 |
Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Chemistry, Pharmaceutical; Drug Stability; Drug Storage; Ethanol; Fema | 2008 |
Relationship of protoporphyrin IX synthesis to photodynamic effects by 5-aminolaevulinic acid and its esters on various cell lines derived from the skin.
Topics: Aminolevulinic Acid; Cell Death; Cell Line; Dose-Response Relationship, Drug; Esters; Flow Cytometry | 2008 |
The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA).
Topics: Aminolevulinic Acid; Cells, Cultured; Heme; Humans; Lymphocyte Activation; Lymphocytes; Mitogens; Ph | 1995 |
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Division; | 1994 |
Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Microscopy, Fluorescenc | 1994 |
Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Female; Injections, | 1996 |
Dosimetry model for photodynamic therapy with topically administered photosensitizers.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Biological Transport, Active; Dogs; Models, B | 1996 |
Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues.
Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Drug Interactions; Humans; Live | 1997 |
Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin.
Topics: Aminolevulinic Acid; Animals; Female; Fluorescence; Male; Mice; Mice, Hairless; Neoplasms, Radiation | 1999 |
Active and higher intracellular uptake of 5-aminolevulinic acid in tumors may be inhibited by glycine.
Topics: Aminolevulinic Acid; Animals; Biological Transport; Cricetinae; Deferoxamine; Diffusion Chambers, Cu | 1999 |
The temperature dependence of protoporphyrin IX production in cells and tissues.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Cell Line; Cricetinae; Female; Humans; Mice; | 1999 |
Preclinical study in cats of the pro-photosensitizer 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Biotransformation; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell | 1999 |
Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application.
Topics: Abdomen; Administration, Topical; Adult; Aged; Aminolevulinic Acid; Facial Dermatoses; Humans; Lymph | 2000 |
Protoporphyrin IX fluorescence kinetics and localization after topical application of ALA pentyl ester and ALA on hairless mouse skin with UVB-induced early skin cancer.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Fluorescence; Mice; Mice, Hairless; Neoplasms | 2000 |
An affordable, portable fluorescence imaging device for skin lesion detection using a dual wavelength approach for image contrast enhancement and aminolaevulinic acid-induced protoporphyrin IX. Part II. In vivo testing.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Female; Humans; Mice; Mice, Inbred BALB C; Phot | 2001 |
ALA and ALA hexyl ester-induced porphyrin synthesis in chemically induced skin tumours: the role of different vehicles on improving photosensitization.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Female; Kidney; Liver; Mice; Neoplas | 2001 |
Protoporphyrin IX fluorescence kinetics in UV-induced tumours and normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Female; Fluorescence; Kinetics; Mice; Mice, H | 2002 |